# Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis

> **NCT05359315** · — · UNKNOWN · sponsor: **SPP Pharmaclon Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Interferon-Gamma

## Key facts

- **NCT ID:** NCT05359315
- **Lead sponsor:** SPP Pharmaclon Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-15
- **Primary completion:** 2022-08-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359315, "Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05359315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*